Expert Ratings for Bicycle Therapeutics
Portfolio Pulse from Benzinga Insights
Bicycle Therapeutics (NASDAQ:BCYC) has received six analyst ratings in the last quarter, all of which are bullish. The average price target is $49.67, indicating a potential upside from the current price of $23.14. The average price target has increased by 6.43% over the past month.
August 04, 2023 | 3:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bicycle Therapeutics has received positive analyst ratings, which could potentially drive the stock price up.
Analyst ratings often influence investor sentiment and can drive stock prices. In this case, Bicycle Therapeutics has received six bullish ratings, which indicates a positive outlook for the stock. This could potentially lead to an increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100